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 ORIGINAL ARTICLE 
 Second cancers after childhood cancer  – GPs beware! 
 A. J.  BERENDSEN 1 ,  A. GROOT  NIBBELINK 1,2 ,  R.  BLAAUWBROEK 1,2 ,
 M. Y.  BERGER 1  &  W. J. E.  TISSING 2 
 1 Department of General Practice, University of Groningen, University Medical Center Groningen, the Netherlands, 
 2 Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, the Netherlands 
 Abstract 
 Background . One of the long-term effects in childhood cancer survivors (CCS) is the development of second cancers. In a 
cohort of CCS, this study describes how second cancers were presented, the way they were diagnosed, and the knowledge 
CCS had about their increased risk to develop a second cancer.  Patients and methods . Selected participants were all adult 
fi ve-year CCS (n    1275) who were treated at the University Medical Center Groningen since 1965. Of these, 84 (6.6%) 
had developed a second cancer, of which 27 had died. The 57 survivors were asked to participate in a telephone interview. 
 Results . Of the 57 CCS, 35 (61%) participated. Together they had developed 45 second cancers. Most participants (97%) 
were seen at the long-term follow-up clinic. Of all second cancers, 89% caused symptoms. Of all second cancers, the 
majority (56%) were fi rst presented at the general practitioner ’ s (GP ’ s) offi ce and 20% at follow-up testing. Of these CCS, 
only 28% were aware of their increased risk of developing a second cancer.  Conclusions . It is important to inform CCS 
continuously regarding their increased risk, as a relatively small percentage are aware of this. Since most of these patients 
fi rst reported their symptoms to the GP, all GPs should be aware of this increased risk, in particular because this concerns 
cancer at a younger age than normally expected. A survivor care plan might be an effective way of communication with 
both CCS and GPs. 
 Key Words:  Childhood cancer survivors ,  general practice ,  general practitioner ,  long-term follow-up ,  second cancers ,  The Netherlands 
care for this group [16,17]. Risk classifi cation in rela-
tion to the fi rst cancer and received treatment is a 
guiding principle in this discussion [17]. Many 
medical centers decided to follow CCS in special 
long-term follow-up (LTFU) clinics. Also, because 
possible long-term effects comprise a large range of 
diseases a generalist, e.g. a general practitioner (GP), 
seems the most appropriate person to perform this 
type of follow-up for adult survivors [18]. 
 One of the long-term effects in CCS is the devel-
opment of a second cancer. In several cohorts risk 
ratios were six times higher as compared with the 
general population: the cumulative incidence was 
3 – 4% after 20 years [13,19]. Risk factors are history 
of radiation therapy (usually    10 years after treat-
ment) [13,19,20], history of chemotherapy (usually 
3 – 5 years after treatment) [21 – 23], and an indi-
vidual factor (gender, younger age at diagnosis, 
 Introduction 
 In the Netherlands, each year about 550 children are 
newly diagnosed with cancer. Due to more effective 
treatment, the survival of childhood cancer has 
improved to an almost 80% fi ve-year survival rate 
[1,2]. This improved prognosis implies a consider-
able increase in the number of survivors of childhood 
cancer [3] . 
 Unfortunately, about two-thirds of adult child-
hood cancer survivors (CCS) suffer from long-term 
morbidity, due to long-term effects of the disease and 
its treatment [4,5]. Examples of associated health 
problems are cognitive damage, growth retardation, 
infertility, decreased cardiac function, endocrine 
insuffi ciency [6 – 12], and second cancers [13 – 15]. 
 It is generally accepted that because of these late 
effects CCS need long-term follow-up; however, dis-
cussion continues regarding the best way to provide 
 Correspondence: A. J. Berendsen, University of Groningen, UMCG, Department of General Practice (FA20), PO Box 196, 9700 AD Groningen, 
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type of fi rst cancer, genetic predisposition) [13,14, 
22,24,25]. 
 When discussing where the long-term follow-up 
of adult survivors with regard to second cancers 
should take place, it is important to know where and 
how the diagnosis of a second cancer was made. 
Therefore, we studied how the second cancers were 
presented, the way they were diagnosed, and the 
knowledge CCS had about their increased risk of 
developing a second cancer. 
 Material and methods 
 Patients 
 For this descriptive study we selected patients with 
a second cancer from all adult fi ve-year CCS 
(n    1275) who were treated at the University 
Medical Center Groningen (UMCG) between 1965 
and 2005. According to the guidelines of the Dutch 
Childhood Oncology Group, patients are invited to 
visit the LTFU clinic (pediatric department) at 
varying intervals, once every 1 – 5 years. Some 
patients also receive follow-up testing from other 
specialists (e.g. neurologists after a brain tumor). 
All characteristics of these adults are known, includ-
ing data on the fi rst cancer, its treatment (e.g. sur-
gery, chemotherapy  – type and dosage, radiation 
therapy  – fi eld and dosage), complications and the 
occurrence of late effects, such as a second cancer. 
Our defi nition of a second cancer included not only 
malignant tumors but also benign tumors such 
as meningiomas and cerebral hemangiomas, as 
reported by others [25]. The selected adult CCS 
were contacted by letter. 
 Structured interview 
 After providing informed consent, between April 
and September 2010 a structured interview was 
conducted by telephone by a researcher (AG). The 
questions were developed by a pediatric oncologist 
and a GP. To improve face and content validity, the 
concept questions were discussed with two senior 
researchers and piloted on three CCS visiting the 
LTFU clinic. The interview questions are listed in 
Table I. 
 In the fi rst part of the interview patients were 
asked about the symptoms they had at the time the 
second cancer was diagnosed, how the diagnosis was 
made, and by whom. The period of time between the 
CCS fi rst noticing symptoms and the fi rst visit to 
a physician was defi ned as  ‘ patient ’ s interval ’ . 
The period of time between the presentation at the 
physician and diagnosis was defi ned as  ‘ diagnostic 
interval ’ [26]. Both intervals were categorized into 
six time periods (  week; 1 week – 1 month; 1 – 3 
months; 3 – 6 months; 6 months – 1year;    1 year). The 
second part of the interview included questions con-
cerning the information given to the patient in the 
past about the risk of developing a second cancer. 
 Data were analyzed by descriptive methods 
(Mann – Whitney test), using SPSS. A p-value    0.05 
was considered signifi cant. 
 Results 
 Characteristics 
 The median follow-up period for the entire cohort 
(n    1275) was 28 years (range 8 – 44). Of the 84 
(6.6%) patients with a second cancer, 27 had died. 
Of the remaining 57 CCS, 35 (61%) agreed to 
participate. Table II shows the characteristics of par-
ticipants and non-participants. Almost all (34/35; 
97%) participants were seen at the LTFU clinic 
with an interval range of 1 – 6/7 years. The 35 par-
ticipants developed 45 second cancers. Median age 
at fi rst cancer was fi ve years while median age at 
second cancer was 27 years. Brain tumors were the 
 Childhood cancer survivors are at risk of  •
late effects such as development of second 
cancers. 
 Follow-up testing for late effects is advised  •
in long-term effects clinics, but is still 
debated with regard to second cancers. 
 Awareness is advised among GPs about the  •
risk of second cancers as most are diagnosed 
by the GP. 
 Table I. Questions asked in interview with participants. 
Questions
Part 1 Who diagnosed the presence of your second cancer?
Did you have any symptoms?
If yes:
• What symptoms did you have?
 • How long did it take before you told a doctor about 
your complaints?
• How long did it take before a diagnosis was made 
after you had seen a doctor?
 • If there was a  ‘ delay ’ , what was the reason for this?
If not:
• How was the second cancer diagnosed?
 Please explain … … .
Part 2 Did you know about the increased risk of a second 
cancer after childhood cancer?
If so, who told you?
Do you think it is important to have this information?
If so, why?
What is the best moment to receive this information?
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most common second cancers, in particular menin-
giomas and hemangiomas. 
 Of the second cancers, radiotherapy was (part of) 
primary treatment in 41/45 (91%). Of these 41 
second cancers, 32 appeared in the previously irradi-
ated area, mostly brain tumors (n    17) and basal-
cell carcinomas (BCC; n    10). The nine second 
cancers which developed after radiotherapy, but not 
in the irradiated area, were melanoma (n    2), brain 
tumor (n    1), chondrosarcoma, sigmoid carcinoma, 
endometrial carcinoma, carcinoid, rectal cancer, and 
testicular cancer. 
 Symptoms of second cancers 
 Of the 45 second cancers, fi ve (11%) did not cause 
any clinical symptoms (Table III). The remaining 
40 (89%) second cancers caused symptoms, most 
frequently skin changes, a palpable tumor, and neu-
rological symptoms. Of the 18 brain tumors found, 
14 (78%) caused neurological symptoms. All 10 
BCC caused symptoms of itching skin, skin changes, 
poor healing, or cosmetically undesirable skin marks. 
The two breast cancers were palpated by the CCS 
themselves. 
 Place of presentation 
 Second cancers were found at routine follow-up 
testing (LTFU clinic, or other medical specialist), 
GPs ’ offi ces, medical specialists ’ offi ces (visited by 
CCS for other health problems), or emergency 
departments. 
 At routine follow-up testing 9/45 (20%) of the 
second cancers were fi rst presented (Table III). Of 
these, four (two BCC and two brain tumors) caused 
symptoms. Four brain tumors (benign) and a carci-
noid caused no symptoms and were diagnosed 
while testing for local relapse of the primary cancer. 
Therefore, all fi ve second cancers that did not lead 
to any symptoms were diagnosed at follow-up. 
 All 25/45 (56%) second cancers diagnosed by 
GPs caused symptoms: seven brain tumors and six 
BCCs, two breast cancers, one melanoma, one 
thyroid carcinoma, and eight other cancers. The 
two breast cancers were not actively screened 
because of the young age of the patient. Seven second 
cancers (16%) were diagnosed by medical special-
ists because patients visited them for other health 
 Table II. Characteristics of the 35 participants and 22 
non-participants and their second cancers (45/25). 
Participants 
(n    35)
Non-participants 
(n    22)
Male gender, 1 n (%) 16 (46%) 7 (32%)
Follow-up time in years 1 
median (range)
29 (12 – 44) 25 (10 – 38)
Age at fi rst cancer in years 1 
median (range)
5 (0 – 15) 7.5 (2 – 16)
Age at second cancer in years 1 
median (range)
27 (9 – 49) 27.5 (7 – 38)
Time (in years) since last visit
 to LTFU clinic n (%)
   1 14 (40%) 4 (19%)
1 – 2 3 (9%) 4 (19%)
2 – 3 4 (11%) 5 (23%)
3 – 4 3 (9%) 3 (14%)
5 – 6 7 (20%) 2 (0%)
6 – 7 3 (9%) 3 (14%)
Unknown 1 (3%) 1 (4%)
Second cancers n    45
 n (%)
n    25
 n (%)
Brain tumor 18 (40%) 9 (36%)
BCC 2 10 (22%) 6 (24%)
Melanoma 4 (9%) 0 (0%)
Breast cancer 2 (5%) 3 (12%)
Other 3 11 (24%) 7 (28%)
 Notes:  1 No signifi cant difference between participants and non-
participants (Mann-Whitney test).  2 BCC basal-cell carcinoma. 
 3 For example, thyroid carcinoma, osteosarcoma, urothelial carci-
noma, sigmoid carcinoma, tongue carcinoma, and ovarian cancer. 





















Brain tumor 14 4 6 3 3 7 1 4
BCC 10 0 2 2 0 6 2 0
Melanoma 4 0 0 1 3 0
Mammary ca. 2 0 0 2 0 0
Thyroid ca. 1 0 0 1 0 0
Osteosarcoma 1 0 0 0 1 0
Other 8 1 1 0 1 8 0 0
Total 40 (89%) 5 (11%) 9 (20%) 5 (11%) 4 (9%) 25 (56%) 7 (16%) 4 (8%)
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problems. Four (8%) second cancers were diagnosed 
at the emergency department (all brain tumors). 
 Interval in diagnosis 
 Data on patient ’ s interval and diagnostic interval 
as reported by the participants are presented in 
Table IV. The patient ’ s interval for BCC was one 
year or longer for 6/10 (60%). Diagnostic interval 
for brain tumors was short: 11/13 (85%) were diag-
nosed within one month. 
 Second cancers with a diagnostic interval of about 
three months were sigmoid carcinoma, cervical car-
cinoma, melanoma, and thyroid carcinoma. Rectal 
carcinoma, chondrosarcoma, melanoma, and testicu-
lar cancer involved a diagnostic interval of about six 
months, and one BCC was diagnosed (diagnostic 
interval) after more than one year. 
 Patient ’ s knowledge 
 Of the CCS, 10/35 (28%) reported they were aware 
of the increased risk of developing a second cancer. 
Of these, seven (70%) reported they were informed 
at the LTFU clinic. Most CCS 30/35 (86%) consid-
ered it important to be informed about this risk. 
 Reasons for better information (as reported by 
the CCS) were: knowledge causes greater alertness, 
reduces the shock at diagnosis of second cancers, and 
one should be informed about everything (Table V). 
Five participants thought it better not to be informed 
because information causes anxiety and revival of 
bad memories. 
 Discussion 
 This study investigated the presentation of second 
cancers and the way they were diagnosed. We chose 
a structured interview to ensure that patients clearly 
understood all questions. Almost all participants 
(97%) were seen at the LTFU clinic. Of the second 
cancers, 56% were diagnosed at a GP ’ s offi ce and 
only 20% at follow-up testing. Remarkably, 89% of 
the second cancers caused symptoms. Patient ’ s inter-
vals were relatively long for BCCs. Only 28% of the 
CCS were aware of the increased risk of developing 
a second cancer. 
 In the present cohort the incidence of second 
cancers is 6.6% (median follow-up 28 years), 
which is comparable to other reports [14,21,22]. 
Radiotherapy was (part of) primary treatment in 
91% of the second cancers; of these second 
cancers, 22% did not occur in the irradiated area. 
This implies that a number of the second cancers 
might not be caused by the therapy received. In 
our cohort the most common second cancers were 
brain tumors and most of these (78%) caused neu-
rological symptoms. Physicians seem to be alert, 
since all brain tumors were diagnosed within one 
month after presentation. However, 21% of the 
CCS who developed a brain tumor had a patient ’ s 
interval of more than one year, even though they 
had symptoms. 
 This fi rst study on symptoms of second cancers 
and the way they were diagnosed in CCS is impor-
tant, as it might affect our viewpoint concerning 
whether surveillance is needed for second cancers. 
Although one study suggested that specifi c screening 
for second cancers in CCS is necessary [14], we 
found that only 20% of second cancers were diag-
nosed at routine follow-up. Considering that almost 
all CCS (97%) were seen at the LTFU clinic, this 
percentage is not high. It is possible that the interval 
 Table IV. Patient ’ s interval and diagnostic interval of 








Patient ’ s interval
   1 week 14 (35%) 8 (57%)
1 week – 1 month 10 (25%) 3 (21.5%) 2 (20%)
1 month – 3 months 4 (10%) 2 (20%)
3 months – 6 months
 6 months – 1 year
2 (5%)
   1 year 10 (25%) 3 (21.5%) 6 (60%)
Total 40 14 10
Diagnostic interval
   1 week 14 (35%) 7 (50%) 2 (20%)
1 week – 1 month 16 (40%) 7 (50%) 7 (70%)
1 month – 3 months 4 (10%)
3 months – 6 months
 6 months – 1 year
5 (12.5%)
   1 year 1 (2.5%) 1 (10%)
Total 40 14 10
 Notes: Patient ’ s interval: time period between the CCS fi rst 
noticing symptoms and fi rst visit to a physician. Diagnostic 
interval: time period between presentation to a physician and the 
diagnosis. 
 Table V. Participants ’ opinion about receiving information 





risk of second 
cancers
Alertness 7 (23%)
To be prepared/less shock at 
actual diagnosis of second 
cancer
7 (23%)
Clarifi cation/one should know 
everything possible
8 (27%)
No reason 8 (27%)
Best moment to 
inform CCS of 
the increased 
risk
At the end of the treatment of 
primary cancer
7 (23%)
After cure/when returning to 
the LTFU clinic
7 (23%)
Do not know 16 (54%)
 Note:  1 Five participants thought it better  not to be informed 
because information causes anxiety and revival of bad memories. 
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between the LTFU visits is too long to diagnose a 
second cancer in a timely manner. In the Nether-
lands, late effects surveillance is guided by national 
guidelines, with strict advice on how to perform 
follow-up. The interval of once every 1 – 5 years 
depends on diagnosis and treatment. Only breast 
cancer screening is advised as second cancer screen-
ing. However, in the present study, patients with 
breast cancer did not meet the criteria for screening 
since they were too young. The four asymptomatic 
brain tumors (meningiomas) were found by means 
of routine check-up when searching for local relapses 
of the primary cancer. However, brain tumors often 
cause symptoms and these CCS usually see a physi-
cian sooner or later. Also, there is no reason for sur-
gery if a meningioma is asymptomatic. Therefore, 
follow-up testing for secondary brain tumors might 
not be indicated. 
 In our cohort, since most second cancers caused 
symptoms and were fi rst presented to the GP, it is 
important that GPs are aware of the higher risk 
CCS have of developing a second cancer, even after 
many decades. Moreover, GPs might not expect 
some cancer types at this (younger) age. 
 Symptoms were often reported after a long 
patient ’ s interval. This is probably (partly) due to the 
fact that only 28% of the CCS knew about their 
increased risk. One reason for this low percentage 
might be that the information was provided a long 
time ago; moreover, the information might not be 
remembered due to the patient ’ s emotional state 
at that time. As suggested earlier, repeating the 
information and checking the knowledge obtained 
might be helpful [27]. CCS said they want to be 
better informed and this might reduce the patient ’ s 
interval. A survivorship care plan made at the end of 
treatment and given to CCS and GPs might be an 
effective means of communication [18]. 
 Strengths and weaknesses 
 Little is known about how CCS with second cancers 
present to the healthcare system. This study is the 
fi rst to examine the presenting symptoms and to 
describe where these patients are diagnosed. 
 We do realize that the study population is rather 
small. Besides, the retrospective nature of the study 
implies some recall bias that may affect the accuracy 
of the data (e.g. dates and presenting symptoms). 
However, given the very large percentage of second 
cancers not presented at follow-up testing, we feel 
that the conclusion of better knowledge for both 
patients and GPs is justifi ed and important. Larger 
studies on this topic are warranted. 
 Not all second cancers might be known at the 
hospital and they might be underreported. This 
will not infl uence the present data, since we studied 
presentation and knowledge about second cancers 
and not, for example, the incidence. 
 In conclusion, only 20% of the second cancers 
were diagnosed by follow-up testing. Follow-up test-
ing in special LTFU clinics seems less effi cient: the 
interval between the LTFU visits might be too long 
to diagnose a second cancer in a timely manner. 
 It is important to educate CCS continuously 
about their increased risk, as only 28% of our study 
population were aware of this. 
 Because the majority of patients fi rst reported 
symptoms to the GP, we think GPs should be aware 
of this increased risk as it concerns cancer at a 
younger age than one would generally expect [28]. 
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